{"id":"yasmin","rwe":[],"tags":[],"safety":{"boxedWarnings":["WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke [see Contraindications ( 4 )] . WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing in"],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Premenstrual syndrome","drugRate":"13.2%","severity":"common","organSystem":""},{"effect":"Headache/migraine","drugRate":"10.7%","severity":"common","organSystem":""},{"effect":"Breast pain/tenderness/discomfort","drugRate":"8.3%","severity":"common","organSystem":""},{"effect":"Nausea/vomiting","drugRate":"4.5%","severity":"common","organSystem":""},{"effect":"Abdominal pain/tenderness/discomfort","drugRate":"2.3%","severity":"common","organSystem":""},{"effect":"Mood changes","drugRate":"2.3%","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Pulmonary embolism","drugRate":"","severity":"serious"},{"effect":"Venous and arterial thromboembolic events","drugRate":"","severity":"serious"},{"effect":"Deep vein thrombosis","drugRate":"","severity":"serious"},{"effect":"Stroke","drugRate":"","severity":"serious"},{"effect":"Myocardial infarction","drugRate":"","severity":"serious"},{"effect":"Depression","drugRate":"","severity":"serious"},{"effect":"Intracranial venous sinus thrombosis","drugRate":"","severity":"serious"},{"effect":"Uterine leiomyoma","drugRate":"","severity":"serious"},{"effect":"Toxic skin eruption","drugRate":"","severity":"serious"},{"effect":"Retinal vein occlusion","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL1509","moleculeType":"Small molecule","molecularWeight":"366.50"},"aliases":["drospirenone and ethinyl estradiol tablets","OCP","combined oral contraceptive"],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T12:29:14.798701","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Yasmin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:15:37.209119+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:15:43.811953+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Yasmin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:15:44.440980+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Progesterone receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:15:45.160999+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1509/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:15:45.070539+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"d7ea6a60-5a56-4f81-b206-9b27b7e58875","title":"YASMIN (DROSPIRENONE AND ETHINYL ESTRADIOL) KIT [BAYER HEALTHCARE PHARMACEUTICALS INC.]"},"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-28T00:16:22.901Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:15:46.927750+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[],"indications":{"approved":[],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(137)"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07074327","phase":"PHASE1","title":"Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-07-11","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":74},{"nctId":"NCT07340190","phase":"PHASE1","title":"A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":"Advanced Malignancies","enrollment":24},{"nctId":"NCT07318337","phase":"NA","title":"Effect of Drospirenone-Ethinyl Estradiol (20microgram vs 30 Microgram) on Free Androgen Index in PCOS","status":"COMPLETED","sponsor":"Mst.Sumyara Khatun","startDate":"2024-07-01","conditions":"PCOS (Polycystic Ovary Syndrome)","enrollment":60},{"nctId":"NCT03819140","phase":"PHASE4","title":"Continuous Versus Cyclical OCP Use in PCOS","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-04-01","conditions":"Polycystic Ovary Syndrome","enrollment":51},{"nctId":"NCT07181343","phase":"PHASE1","title":"A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®)","status":"COMPLETED","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-05-28","conditions":"Psoriasis (PsO)","enrollment":18},{"nctId":"NCT06820307","phase":"PHASE1","title":"Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-02-25","conditions":"Pain","enrollment":50},{"nctId":"NCT05934942","phase":"PHASE1","title":"A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2023-09-08","conditions":"Healthy","enrollment":29},{"nctId":"NCT06608186","phase":"PHASE1, PHASE2","title":"Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!","status":"COMPLETED","sponsor":"Ahmed Saad","startDate":"2024-10-01","conditions":"PCOS (Polycystic Ovary Syndrome)","enrollment":50},{"nctId":"NCT05098574","phase":"PHASE2","title":"Oral Contraceptives for Treating Premenstrual Dysphoric Disorder in Bipolar Disorder","status":"COMPLETED","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2023-02-03","conditions":"Premenstrual Dysphoric Disorder, Bipolar Disorder","enrollment":17},{"nctId":"NCT06250205","phase":"PHASE1","title":"Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib","status":"COMPLETED","sponsor":"NewAmsterdam Pharma","startDate":"2024-02-05","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT06577974","phase":"NA","title":"Role of Medical Treatment in Endometriosis Patients Undergoing ICSI","status":"RECRUITING","sponsor":"Cairo University","startDate":"2024-07-01","conditions":"Endometriosis","enrollment":129},{"nctId":"NCT01277211","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-09-19","conditions":"Contraception","enrollment":983},{"nctId":"NCT05872425","phase":"NA","title":"Efficacy and Safety of Dingkundan Combined With Combination Oral Contraceptives in the Treatment of PCOS","status":"COMPLETED","sponsor":"Guangdong Women and Children Hospital","startDate":"2023-02-01","conditions":"PCOS","enrollment":120},{"nctId":"NCT06233071","phase":"PHASE1","title":"Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz®","status":"RECRUITING","sponsor":"Bio-innova Co., Ltd","startDate":"2024-02-13","conditions":"Healthy Subjects","enrollment":32},{"nctId":"NCT06233058","phase":"PHASE1","title":"Drospirenone (3 mg) + Ethinyl Estradiol (0.03 mg) Tablets Relative to Yasmin®","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-03-05","conditions":"Healthy Subjects","enrollment":32},{"nctId":"NCT05985590","phase":"PHASE1","title":"A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-08-18","conditions":"Healthy Volunteers","enrollment":37},{"nctId":"NCT03091595","phase":"PHASE2","title":"E4/DRSP Ovarian Function Inhibition Study","status":"COMPLETED","sponsor":"Estetra","startDate":"2017-02-07","conditions":"Prevention of Pregnancy","enrollment":82},{"nctId":"NCT04984070","phase":"NA","title":"Research on Risk Factors and Interventions of Polycystic Ovary Syndrome Complicated With Depression and Anxiety","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-01-01","conditions":"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Depression, Anxiety","enrollment":100},{"nctId":"NCT04278755","phase":"PHASE2","title":"Binge Eating & Birth Control","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2020-09-24","conditions":"Bulimia Nervosa, Binge Eating, Eating Disorders","enrollment":8},{"nctId":"NCT04831151","phase":"NA","title":"The Effect of Polycystic Ovary Syndrome Treatment on Metabolomics","status":"UNKNOWN","sponsor":"Inonu University","startDate":"2021-03-01","conditions":"Polycystic Ovary Syndrome","enrollment":42},{"nctId":"NCT00413062","phase":"PHASE3","title":"Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06","conditions":"Contraception","enrollment":2281},{"nctId":"NCT05156879","phase":"PHASE4","title":"Aspirin for the Management of Endometriosis-associated Pelvic Pain","status":"UNKNOWN","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2021-12-23","conditions":"Pelvic Pain","enrollment":220},{"nctId":"NCT01291004","phase":"PHASE1","title":"A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2011-01-31","conditions":"Follicle Development, Ovarian Follicle, Follicle Count","enrollment":206},{"nctId":"NCT03126773","phase":"","title":"A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-05-02","conditions":"Menopause","enrollment":1570},{"nctId":"NCT04256200","phase":"PHASE2, PHASE3","title":"Efficacy of Dienogest Versus Oral Contraceptive Pills on Pain Associated With Endometriosis","status":"UNKNOWN","sponsor":"American University of Beirut Medical Center","startDate":"2017-02-07","conditions":"Endometriosis","enrollment":100},{"nctId":"NCT01805817","phase":"PHASE4","title":"Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality","status":"WITHDRAWN","sponsor":"Istanbul Training and Research Hospital","startDate":"2012-12","conditions":"Contraceptive Methods Comparison","enrollment":""},{"nctId":"NCT03353857","phase":"PHASE1","title":"Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-11-29","conditions":"Biological Availability","enrollment":68},{"nctId":"NCT04296422","phase":"NA","title":"Different Does of Acupuncture on Premenstrual Syndrome Efficacy Analysis","status":"UNKNOWN","sponsor":"Taipei City Hospital","startDate":"2019-01-01","conditions":"Premenstrual Syndrome","enrollment":105},{"nctId":"NCT03843736","phase":"PHASE3","title":"The Role of Dysbiosis of Gut Microbiota in the Pathogenesis of PCOS.","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-02-21","conditions":"Polycystic Ovary Syndrome","enrollment":200},{"nctId":"NCT02710708","phase":"PHASE4","title":"YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-05-27","conditions":"Contraception","enrollment":1921},{"nctId":"NCT00745901","phase":"PHASE4","title":"Study to Evaluate Cycle Control With Norgestimate/Ethinyl Estradiol and Drospirenone/Ethinyl Estradiol in Healthy Sexually Active Females","status":"COMPLETED","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2008-05","conditions":"Contraception","enrollment":355},{"nctId":"NCT03881319","phase":"NA","title":"The Efficacy of Different Doses of Acupuncture in Dysmenorrhea","status":"UNKNOWN","sponsor":"Taipei City Hospital","startDate":"2018-06-01","conditions":"Premenstrual Syndrome, Dysmenorrhea","enrollment":105},{"nctId":"NCT01375998","phase":"","title":"YAZ Post-marketing Surveillance in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-06-09","conditions":"Dysmenorrhea","enrollment":3273},{"nctId":"NCT01195974","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2010-09-14","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":13},{"nctId":"NCT00640224","phase":"PHASE4","title":"Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study","status":"COMPLETED","sponsor":"Silva Arslanian","startDate":"2005-03","conditions":"Polycystic Ovary Syndrome","enrollment":65},{"nctId":"NCT01254292","phase":"PHASE3","title":"LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-01-06","conditions":"Contraception","enrollment":567},{"nctId":"NCT01557023","phase":"PHASE3","title":"Clinical Trial With Combination of Dienogest/Ethytnilestradiol and Drosperidona/Ethyniestradiol","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2013-07-01","conditions":"Metrorrhagia","enrollment":""},{"nctId":"NCT03111511","phase":"PHASE1","title":"A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe Substrate for Cytochrome P450 3A4)","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2017-03-27","conditions":"Healthy","enrollment":18},{"nctId":"NCT00089414","phase":"PHASE2","title":"Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives","status":"TERMINATED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2004-07","conditions":"Premenstrual Syndrome, PMS, Premenstrual Dysphoric Disorder","enrollment":5},{"nctId":"NCT02841202","phase":"PHASE4","title":"The Effect of Oral Contraceptive Pills On Eyes","status":"COMPLETED","sponsor":"Kayseri Education and Research Hospital","startDate":"2014-01","conditions":"Adverse Effect of Oral Contraceptives, Subsequent Encounter","enrollment":40},{"nctId":"NCT02159261","phase":"","title":"Assess Satisfaction of Patients and Physicians With Results of Yaz Plus Treatment for 13 Cycles","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-07-15","conditions":"Contraception","enrollment":1500},{"nctId":"NCT03124524","phase":"PHASE4","title":"Treatment Choice in Primary Dysmenorrhea","status":"COMPLETED","sponsor":"Adana Numune Training and Research Hospital","startDate":"2015-01-15","conditions":"Primary Dysmenorrhea","enrollment":99},{"nctId":"NCT00633360","phase":"NA","title":"The Oral Contraceptive Pill for Premenstrual Worsening of Depression","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-02","conditions":"Premenstrual Syndrome, Depression","enrollment":32},{"nctId":"NCT03037944","phase":"EARLY_PHASE1","title":"Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri","status":"UNKNOWN","sponsor":"Ain Shams Maternity Hospital","startDate":"2016-03-01","conditions":"Adenomyosis","enrollment":32},{"nctId":"NCT02885454","phase":"PHASE1","title":"To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08","conditions":"Healthy","enrollment":24},{"nctId":"NCT02488538","phase":"PHASE3","title":"Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in Severe Premenstrual Syndrome","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2015-07","conditions":"Premenstrual Syndrome","enrollment":300},{"nctId":"NCT00927095","phase":"PHASE4","title":"Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2008-07","conditions":"Premenstrual Dysphoric Disorder","enrollment":67},{"nctId":"NCT02855294","phase":"PHASE4","title":"The Effect of Oral Contraceptives on Women Balance","status":"COMPLETED","sponsor":"Cairo University","startDate":"2015-01","conditions":"Joint Stabilioty","enrollment":100},{"nctId":"NCT01109979","phase":"PHASE4","title":"Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2009-12","conditions":"Cardiovascular Diseases","enrollment":24},{"nctId":"NCT02562053","phase":"PHASE3","title":"Does Adding Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome?","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2015-10","conditions":"Premenstrual Syndrome","enrollment":300},{"nctId":"NCT02757469","phase":"NA","title":"Oral Contraceptives as Infertility Treatments for Premature Ovarian Failure","status":"UNKNOWN","sponsor":"Navy General Hospital, Beijing","startDate":"2016-05","conditions":"Primary Ovarian Insufficiency, Menopause, Premature","enrollment":20},{"nctId":"NCT02681536","phase":"NA","title":"Miniflare Versus Long Protocol in Poor Responders","status":"UNKNOWN","sponsor":"Woman's Health University Hospital, Egypt","startDate":"2016-02","conditions":"Infertility","enrollment":200},{"nctId":"NCT01697111","phase":"PHASE3","title":"Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-10","conditions":"Endometriosis","enrollment":312},{"nctId":"NCT02617537","phase":"PHASE3","title":"To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2016-01","conditions":"Dysmenorrhea","enrollment":""},{"nctId":"NCT00923572","phase":"","title":"Yasmin Post Marketing Surveillance","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-12","conditions":"Contraception","enrollment":777},{"nctId":"NCT01892904","phase":"PHASE3","title":"Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-07","conditions":"Dysmenorrhea","enrollment":216},{"nctId":"NCT00818519","phase":"PHASE3","title":"GA YAZ ACNE in China Phase III","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-12","conditions":"Acne Vulgaris","enrollment":179},{"nctId":"NCT02089620","phase":"PHASE3","title":"Comparison Between Oral Contraceptive Pills and Calcium Supplements in Treatment of Premenstrual Syndrome","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2014-05","conditions":"Premenstrual Syndrome","enrollment":210},{"nctId":"NCT00420342","phase":"PHASE2","title":"Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-01","conditions":"Postmenopause, Hypertension, Pre-Hypertension","enrollment":92},{"nctId":"NCT00283816","phase":"PHASE3","title":"Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2006-01","conditions":"Polycystic Ovary Syndrome","enrollment":36},{"nctId":"NCT00714233","phase":"PHASE3","title":"Treatment of Adolescent Polycystic Ovary Syndrome (PCOS)","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2002-08","conditions":"Polycystic Ovary Syndrome","enrollment":43},{"nctId":"NCT01608698","phase":"PHASE4","title":"Comparison of Body Weight Change During Contraception With Belara and Yasmin","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2012-06","conditions":"Body Weight Changes","enrollment":100},{"nctId":"NCT00998257","phase":"","title":"Regulatory Post Marketing Surveillance Study on YAZ","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-07","conditions":"Contraception, Premenstrual Syndrome, Acne","enrollment":770},{"nctId":"NCT00185484","phase":"PHASE3","title":"Efficacy and Safety Oral Contraceptive Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-03","conditions":"Contraception","enrollment":1113},{"nctId":"NCT00651599","phase":"PHASE3","title":"Treatment of Vasomotor Symptoms in Korean Post Menopausal Women","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-07","conditions":"Vasomotor Symptoms","enrollment":90},{"nctId":"NCT00624130","phase":"PHASE3","title":"Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female Volunteers","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-03","conditions":"Contraception","enrollment":453},{"nctId":"NCT00651846","phase":"PHASE4","title":"Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy Women","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-06","conditions":"Healthy","enrollment":43},{"nctId":"NCT00656981","phase":"PHASE3","title":"Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-01","conditions":"Acne Vulgaris","enrollment":541},{"nctId":"NCT00651469","phase":"PHASE3","title":"Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-01","conditions":"Acne Vulgaris","enrollment":534},{"nctId":"NCT00102141","phase":"PHASE3","title":"Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-04","conditions":"Hypertension, Postmenopause","enrollment":750},{"nctId":"NCT02027337","phase":"PHASE4","title":"Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants","status":"UNKNOWN","sponsor":"Tyumen State Medical Academy","startDate":"2013-12","conditions":"Polycystic Ovarian Syndrome, Hyperandrogenism, Menstrual Irregularities","enrollment":200},{"nctId":"NCT00266032","phase":"PHASE3","title":"Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-12","conditions":"Contraception","enrollment":1166},{"nctId":"NCT00569244","phase":"PHASE3","title":"SH T00186 in the Treatment of Primary Dysmenorrhea","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-12","conditions":"Primary Dysmenorrhea","enrollment":223},{"nctId":"NCT01076582","phase":"PHASE3","title":"Comparative Trial in Hormone Withdrawal Associated Symptoms","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-04","conditions":"Oral Contraceptive","enrollment":592},{"nctId":"NCT00673686","phase":"PHASE2","title":"Study to Investigate the Effect of Missed Pills on Follicular Development in Two Application Regimens of SH T 00186 D","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-05","conditions":"Contraceptives, Oral","enrollment":105},{"nctId":"NCT00356447","phase":"PHASE3","title":"Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-05","conditions":"Vasomotor Symptoms","enrollment":249},{"nctId":"NCT02237131","phase":"PHASE4","title":"Continuous Versus Cyclic Oral Contraceptives for Endometriosis","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2014-04","conditions":"Dysmenorrhea, Pelvic Pain, Dyspareunia","enrollment":50},{"nctId":"NCT00988910","phase":"","title":"Effects of Drospirenone-containing or -Not Containing Combined Oral Contraceptives on General and Sexual Well-being","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-01","conditions":"Contraception","enrollment":632},{"nctId":"NCT00442689","phase":"NA","title":"Metabolic Syndrome in PCOS: Precursors and Interventions","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2006-07","conditions":"Polycystic Ovary Syndrome, Metabolic Syndrome","enrollment":97},{"nctId":"NCT00468481","phase":"PHASE3","title":"Efficacy and Safety Study for an Oral Contraceptive Containing Folate","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-04","conditions":"Neural Tube Defects, Contraception, Oral Contraceptives (OC)","enrollment":385},{"nctId":"NCT00824187","phase":"PHASE3","title":"YAZ Premenstrual Dysphoric Disorder (PMDD) in China","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-01","conditions":"Premenstrual Dysphoric Disorder ( PMDD)","enrollment":187},{"nctId":"NCT00567164","phase":"PHASE3","title":"Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-10","conditions":"Contraception, Ovulation Inhibition, Contraceptives, Oral","enrollment":1887},{"nctId":"NCT00722800","phase":"PHASE2","title":"A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2008-10","conditions":"Hidradenitis Suppurativa","enrollment":4},{"nctId":"NCT01064453","phase":"","title":"Angeliq Regulatory Post Marketing Surveillance","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-06","conditions":"Postmenopausal Period, Osteoporosis, Postmenopausal","enrollment":4078},{"nctId":"NCT00367276","phase":"PHASE3","title":"Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-12","conditions":"Healthy","enrollment":221},{"nctId":"NCT01258660","phase":"PHASE1","title":"Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-12","conditions":"Contraception","enrollment":172},{"nctId":"NCT01253174","phase":"PHASE1","title":"Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-08","conditions":"Contraception","enrollment":48},{"nctId":"NCT01253187","phase":"PHASE1","title":"Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: YAZ and YAZ + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and YAZ + Levomefolate Calcium (Metafolin)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-10","conditions":"Contraception","enrollment":44},{"nctId":"NCT01185678","phase":"","title":"Data on Oral Contraceptives Compliance in Non Stop Regimen","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-05","conditions":"Contraception","enrollment":8416},{"nctId":"NCT01850095","phase":"NA","title":"The Influence of Peripheral Androgen Conversion at Women Adult Acne","status":"UNKNOWN","sponsor":"Marco Alexandre Dias da Rocha","startDate":"2012-03","conditions":"Acne, Quality of Life","enrollment":60},{"nctId":"NCT00722761","phase":"PHASE3","title":"Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-04","conditions":"Acne Vulgaris","enrollment":30},{"nctId":"NCT00819312","phase":"PHASE3","title":"YAZ, Oral Contraceptive Registration in China","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-12","conditions":"Contraception","enrollment":675},{"nctId":"NCT01319500","phase":"","title":"Drug Utilization Study on the Prescribing Indications for Yasmin® and Other OCs in Croatia","status":"COMPLETED","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2009-02","conditions":"Contraception","enrollment":3776},{"nctId":"NCT01603745","phase":"PHASE1","title":"Effects of Drospirenone-ethinylestradiol and/or NOMAC-valerate Estradiol on Cardiovascular Risk in Women With Polycystic Ovary Syndrome","status":"UNKNOWN","sponsor":"Catholic University of the Sacred Heart","startDate":"2012-04","conditions":"Polycystic Ovary Syndrome","enrollment":10},{"nctId":"NCT01590849","phase":"PHASE3","title":"Assessment of Autonomic Tone in Normotensive Women Using Combined Hormonal Oral Contraceptive Containing Drospirenone","status":"UNKNOWN","sponsor":"Instituto do Coracao","startDate":"2011-01","conditions":"Contraceptive Affecting the Autonomic Nervous System, Contraceptive Affecting Blood Pressure","enrollment":69},{"nctId":"NCT01581814","phase":"PHASE3","title":"Effects of Drospirenone-ethinylestradiol and/or Metformin on Cardiovascular Risk in Hyperinsulinemic Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2008-10","conditions":"Polycystic Ovary Syndrome","enrollment":99},{"nctId":"NCT01482338","phase":"PHASE4","title":"Premenstrual Symptoms Treatment Comparing Between Oral Contraceptives Containing Desogestrel and Drospirenone","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2011-06","conditions":"Premenstrual Syndrome","enrollment":90},{"nctId":"NCT00905684","phase":"","title":"Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-06","conditions":"Contraception","enrollment":5446},{"nctId":"NCT01511822","phase":"PHASE4","title":"Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance","status":"COMPLETED","sponsor":"AGUNCO Obstetrics and Gynecology Centre","startDate":"","conditions":"PCOS, Polycystic Ovary Syndrome","enrollment":""},{"nctId":"NCT01198444","phase":"","title":"To Evaluate Compliance to Treatment Regimen (Rate of Deviations From the Prescribed Regimen) in Polish Females Treated With Different Low Dose Oral Contraceptives","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-12","conditions":"Contraception","enrollment":11884}],"_emaApprovals":[],"_faersSignals":[{"count":8582,"reaction":"PAIN"},{"count":7480,"reaction":"INJURY"},{"count":5614,"reaction":"PULMONARY EMBOLISM"},{"count":5409,"reaction":"DEEP VEIN THROMBOSIS"},{"count":4485,"reaction":"ANXIETY"},{"count":4417,"reaction":"EMOTIONAL DISTRESS"},{"count":3614,"reaction":"CHOLECYSTITIS CHRONIC"},{"count":2691,"reaction":"CHOLELITHIASIS"},{"count":2629,"reaction":"GALLBLADDER DISORDER"},{"count":2256,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1509"},"formularyStatus":[],"_approvalHistory":[{"date":"20130131","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA021098"},{"date":"20020808","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA021098"},{"date":"20011212","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA021098"},{"date":"20011130","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA021098"},{"date":"20230519","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA021098"},{"date":"20120213","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA021098"},{"date":"20140930","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA021098"},{"date":"20100407","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA021098"},{"date":"20150601","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA021098"},{"date":"20030509","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA021098"},{"date":"20011130","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA021098"},{"date":"20011126","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA021098"},{"date":"20010511","type":"ORIG","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA021098"},{"date":"20170809","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA021098"},{"date":"20160308","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA021098"},{"date":"20141126","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA021098"},{"date":"20220429","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA021098"},{"date":"20120410","type":"SUPPL","sponsor":"BAYER HLTHCARE","applicationNumber":"NDA021098"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":137,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Yasmin","genericName":"Yasmin","companyName":"Inonu University","companyId":"inonu-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:15:46.927750+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}